|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,040,000 |
Market
Cap: |
174.42(K) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.0855 - $0.0855 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile NovaBay Pharmaceuticals develops and sells eyecare and skincare products. Co.'s primary product, Avenova® Antimicrobial Lid and Lash Solution removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Other eyecare products provided under the Avenova eyecare brand include Novawipes by Avenova, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress, and the i-Chek. Co.'s subsidiary, DERMAdoctor, LLC provides dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration and keratosis pilaris.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
10,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$1,500 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
0 |
0 |
0 |
606,578 |
Total Sell Value |
$0 |
$0 |
$0 |
$142,372 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
8 |
End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pioneer Pharma (hong Kong) Co Ltd |
10% Owner |
|
2013-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
3,913 |
2,005,656 |
|
- |
|
Pioneer Pharma (singapore) Pte. Ltd. |
10% Owner |
|
2013-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,913 |
2,005,656 |
|
- |
|
Pioneer Pharma (hong Kong) Co Ltd |
10% Owner |
|
2013-05-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,001,743 |
|
- |
|
China Pioneer Pharma Holdings Ltd |
10% Owner |
|
2013-05-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,001,743 |
|
- |
|
Li Xinzhou |
10% Owner |
|
2013-04-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,743 |
2,001,743 |
|
- |
|
Pioneer Pharma (singapore) Pte. Ltd. |
10% Owner |
|
2013-04-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,743 |
2,001,743 |
|
- |
|
Li Xinzhou |
Pres.Naqu Area Pioneer Pharma |
|
2012-12-11 |
4 |
B |
$1.20 |
$144,000 |
D/D |
120,000 |
2,120,000 |
2.45 |
- |
|
Stroman David W. |
SVP, Ophthalmic Product Devt. |
|
2012-12-06 |
4 |
B |
$1.24 |
$12,400 |
D/D |
10,000 |
22,000 |
2.74 |
- |
|
Paulson Thomas J |
CFO |
|
2012-12-06 |
4 |
B |
$1.24 |
$12,400 |
D/D |
10,000 |
63,855 |
2.74 |
- |
|
Najafi Ramin |
Chief Executive OfficerChairma |
|
2012-12-06 |
4 |
B |
$1.24 |
$24,800 |
D/D |
20,000 |
100,195 |
3.15 |
- |
|
Li Xinzhou |
10% Owner |
|
2012-10-31 |
4 |
B |
$1.25 |
$1,500,000 |
I/I |
1,200,000 |
2,000,000 |
1.5 |
- |
|
Naqu Area Pioneer Pharma Co., Ltd. |
10% Owner |
|
2012-10-31 |
4 |
B |
$1.25 |
$1,500,000 |
I/I |
1,200,000 |
2,000,000 |
2.64 |
- |
|
Pioneer Pharma (singapore) Pte. Ltd. |
10% Owner |
|
2012-10-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
800,000 |
|
- |
|
Pioneer Pharma (singapore) Pte. Ltd. |
10% Owner |
|
2012-10-31 |
4 |
B |
$1.25 |
$1,500,000 |
D/D |
1,200,000 |
2,000,000 |
2.45 |
- |
|
Naqu Area Pioneer Pharma Co., Ltd. |
10% Owner |
|
2012-10-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
800,000 |
|
- |
|
Najafi Ramin |
Chief Executive OfficerChairma |
|
2012-10-27 |
4 |
D |
$1.31 |
$5,970 |
D/D |
(4,557) |
80,195 |
|
- |
|
Paulson Thomas J |
CFO |
|
2012-10-27 |
4 |
D |
$1.31 |
$4,775 |
D/D |
(3,645) |
53,855 |
|
- |
|
Tufts Robert R. |
Director |
|
2012-09-27 |
4 |
OE |
$0.56 |
$15,960 |
I/I |
28,500 |
348,408 |
|
- |
|
Li Xinzhou |
10% Owner |
|
2012-09-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
800,000 |
|
- |
|
Li Xinzhou |
10% Owner |
|
2012-09-13 |
4 |
B |
$1.25 |
$1,000,000 |
I/I |
800,000 |
800,000 |
1.5 |
- |
|
Paulson Thomas J |
CFO |
|
2012-05-30 |
4 |
B |
$0.94 |
$9,364 |
D/D |
10,000 |
17,500 |
2.74 |
- |
|
Najafi Ramin |
Chief Executive OfficerChairma |
|
2012-05-29 |
4 |
B |
$0.96 |
$5,756 |
D/D |
6,000 |
34,752 |
2.81 |
- |
|
Najafi Ramin |
Chief Executive OfficerChairma |
|
2012-05-25 |
4 |
B |
$0.99 |
$3,465 |
D/D |
3,500 |
28,752 |
2.73 |
- |
|
Freiman Paul E. |
Director |
|
2011-12-29 |
4 |
OE |
$0.20 |
$6,000 |
I/I |
30,000 |
45,137 |
|
- |
|
Najafi Ramin |
Chief Executive OfficerChairma |
|
2011-10-27 |
4 |
A |
$1.09 |
$54,500 |
D/D |
50,000 |
202,673 |
|
- |
|
334 Records found
|
|
Page 5 of 14 |
|
|